Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
With
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Solid cancer for which curative measures have failed or for which there is no known superior treatment
ECOG performance status 0-2
Measurable or non-measurable disease
Life expectancy of greater than 12 weeks and no anticipated need for other antineoplastic therapy in the next 4 weeks
Age 18 years or older
Patients must have adequate organ and marrow function as defined below:
* ALT and AST less than or equal to 2.5 x the ULN (\< 5 x ULN for patients with liver involvement).
* hemoglobin greater than or equal to 9 g/dL
* absolute neutrophil count greater than or equal to 1,500/μL
* platelets greater than or equal to 100,000/μL (greater than or equal to 35,000/μL without transfusion for patients with CLL/SLL or follicular lymphoma)
* total bilirubin less than or equal to 1.5 x ULN
* creatinine less than or equal to 1.5 x ULN
Women of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment.
Ability to understand and the willingness to sign a written informed consent document
Must not have any evidence of bleeding diathesis.
You may not be if
Patients who have had chemotherapy or immunotherapy within 3 weeks or radiotherapy within 14 days prior to entering the study
Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy
Patients with uncontrolled brain metastases.
Concurrent illness or medication exclusions
HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with sorafenib or rapamycin.
